5'-nucleotidase
ATC code L01
ATC code L04
Abatacept
Abemaciclib
Abetimus
Aclarubicin
Acute disseminated encephalomyelitis
Adagrasib
Adalimumab
Adaptive immune system
Adenosine deaminase
Adenosine deaminase deficiency
Adenosine deaminase inhibitor
Adrenoleukodystrophy
Afelimomab
Aflibercept
Alefacept
Alemtuzumab
Alexander disease
Alitretinoin
Alkyl sulfonate
Alkylating antineoplastic agent
Alpelisib
Altretamine
Alvocidib
American Society of Health-System Pharmacists
Aminolevulinic acid
Aminopterin
Amrubicin
Amsacrine
Anagrelide
Anakinra
Anatomical Therapeutic Chemical Classification System
Anemia
Anifrolumab
Anthracycline
Anthraquinone
Anti-lymphocyte globulin
Anti-thymocyte globulin
Antibody
Antifolate
Antimetabolite
Antineoplastic
Apoptosis
Apremilast
Arsenic trioxide
Aselizumab
Asparaginase
Asparagine
Ataxia
Atorolimumab
Atrasentan
Avacopan
Avelumab
Axicabtagene ciloleucel
Azacitidine
Azathioprine
Aziridine
B-cell chronic lymphocytic leukemia
Balo concentric sclerosis
Baricitinib
Basigin
Basiliximab
Begelomab
Belatacept
Belimumab
Belinostat
Belotecan
Belzutifan
Bendamustine
Bertilimumab
Bexarotene
Bimekizumab
Bioavailability
Biological half-life
Bisantrene
Bisoprolol
Bleomycin
Blisibimod
Bone marrow suppression
Bortezomib
Boxed warning
Brexucabtagene autoleucel
Briakinumab
Brodalumab
Busulfan
By mouth
CAMFAK syndrome
CAS Registry Number
CD11a
CD154
CD18
CD20
CD23
CD3 (immunology)
CD4
CD40 (protein)
CD80
CNS demyelinating autoimmune diseases
CTLA-4
Cabazitaxel
Calcineurin
Camptotheca
Camptothecin
Canakinumab
Canavan disease
Capecitabine
Carboplatin
Carboquone
Carfilzomib
Carmofur
Carmustine
Cedelizumab
Celecoxib
Cell-cycle nonspecific antineoplastic agents
Central nervous system
Central pontine myelinolysis
Certolizumab pegol
Cetuximab
ChEBI
ChEMBL
ChemSpider
Chemical formula
Chemotherapy
Chemotherapy regimen
Chlorambucil
Chloramphenicol acetyltransferase
Chlormethine
Chronic inflammatory demyelinating polyneuropathy
Ciclosporin
Ciltacabtagene autoleucel
Cisplatin
Cladribine (data page)
Clenoliximab
Clinical trial
Clinically isolated syndrome
Clofarabine
CompTox Chemicals Dashboard
Complement component 5
Copanlisib
Cositecan
Crisnatol
Crosslinking of DNA
Crovalimab
Cyclin-dependent kinase
Cyclodextrin
Cyclophilin
Cyclophosphamide
Cytarabine
Cytochrome c
DNA polymerase inhibitor
DNA replication
Dacarbazine
Daclizumab
Dactinomycin
DailyMed
Danicopan
Darvadstrocel
Daunorubicin
Daunorubicin/cytarabine
Dawson's fingers
Decitabine
Demecolcine
Denileukin diftitox
Dennis A. Carson
Deoxyadenosine
Deoxycytidine kinase
Deoxyribonucleotide
Deucravacitinib
Deuruxolitinib
Diagnosis of multiple sclerosis
Dicycloplatin
Diffuse myelinoclastic sclerosis
Dihydrofolate reductase inhibitor
Dihydroorotate dehydrogenase
Dimethyl fumarate
Diplopia
Diroximel fumarate
Docetaxel
Doi (identifier)
Doxifluridine
Doxorubicin
DrugBank
Drug metabolism
Drug nomenclature
Drugs.com
Duvelisib
Dysarthria
Dysphagia
ECHA InfoCard
Eculizumab
Efalizumab
Efaproxiral
Efgartigimod alfa
Efgartigimod alfa/hyaluronidase
Eflornithine
Elesclomol
Elsamitrucin
Elsilimomab
Emapalumab
Enasidenib
Endothelin receptor antagonist
Entinostat
Enzyme inhibitor
Epacadostat
Epirubicin
Epothilone
Erdheim–Chester disease
Eribulin
Erlizumab
Ernest Beutler
Estramustine phosphate
Etanercept
Etirinotecan pegol
Etoglucid
Etoposide
Etrasimod
European Medicines Agency
Everolimus
Exatecan
Excretion
Expanded Disability Status Scale
Experimental autoimmune encephalomyelitis
FDA
FKBP
Faralimomab
Farnesyltransferase inhibitor
Fatigue
Filgotinib
Fingolimod
Floxuridine
Fludarabine
Fluorouracil
Fontolizumab
Fotemustine
Frexalimab
Fusion protein
Fuzuloparib
Galiximab
Gavilimomab
Gemcitabine
Gimatecan
Glasdegib
Glatiramer acetate
Golimumab
Gomiliximab
Gonadotropin preparations
Guide to Pharmacology
Guselkumab
Gusperimus
Hairy cell leukemia
Halogenation
Hdl (identifier)
Health Canada
Hereditary CNS demyelinating disease
Histiocytosis
Histone deacetylase inhibitor
Human chorionic gonadotropin
Hydrazine
Hydroxycarbamide
Hypomethylating agent
IL-2 receptor
IMP dehydrogenase
IUPAC nomenclature of chemistry
Idarubicin
Idecabtagene vicleucel
Idelalisib
Ifosfamide
Imetelstat
Immunoglobulin E
Immunomodulatory imide drug
Immunosuppression
Immunosuppressive drug
Inavolisib
Inebilizumab
Inflammatory demyelinating diseases of the central nervous system
Infliximab
Inolimomab
Integrin
Intercalation (biochemistry)
Interferon
Interferon beta-1a
Interferon beta-1b
Interleukin
Interleukin-6 receptor
Interleukin 12
Interleukin 13
Interleukin 17
Interleukin 1 receptor antagonist
Interleukin 2
Interleukin 23
Interleukin 5
Interleukin 6
International Chemical Identifier
Intracellular
Intravenous
Iptacopan
Irinotecan
Isocitrate dehydrogenase
Itacitinib
Ivosidenib
Ixabepilone
Ixazomib
Ixekizumab
JSmol
Johnson & Johnson
KEGG
Keliximab
Kinase
Krabbe disease
L-selectin
Langerhans cell histiocytosis
Laquinimod
Larotaxel
Lebrikizumab
Leflunomide
Lenalidomide
Lerdelimumab
Lesional demyelinations of the central nervous system
Leukoencephalopathy with vanishing white matter
Levothyroxine
Lifileucel
Lipoxygenase inhibitor
Lisocabtagene maraleucel
List of multiple sclerosis organizations
List of people with multiple sclerosis
List of withdrawn drugs
Lomustine
Lonidamine
Losoxantrone
Lucanthone
Lumiliximab
Lurbinectedin
Lurtotecan
Luteinizing hormone
Lymphocyte function-associated antigen 1
Lymphocytes
Lymphocytopenia
MOG antibody disease
MTOR
M phase
Macrolide
Major depressive disorder
Malignancy
Management of multiple sclerosis
Mannosulfan
Marburg acute multiple sclerosis
Marchiafava–Bignami disease
Maslimomab
Masoprocol
McDonald criteria
MedlinePlus
Megalencephalic leukoencephalopathy with subcortical cysts
Melphalan
Melphalan flufenamide
Menogaril
Mepolizumab
Mercaptopurine
Merck Group
Merck KGaA
Merck Serono
Metachromatic leukodystrophy
Metelimumab
Metformin
Methotrexate
Methyl aminolevulinate
Microtubule
Mitobronitol
Mitochondrial DNA depletion syndrome
Mitoguazone
Mitomycins
Mitotane
Mitotic inhibitor
Mitoxantrone
Mitozolomide
Molar mass
Monoclonal antibody
Monomethyl fumarate
Morolimumab
Mouth
Multiple sclerosis
Multiple sclerosis drug pipeline
Muromonab-CD3
Mycophenolic acid
Nadofaragene firadenovec
Natalizumab
Natural killer cells
Navitoclax
Nedaplatin
Nelarabine
Nerelimomab
Netakimab
Neuromyelitis optica spectrum disorder
Neutropenia
Neutrophils
New drug application
Nimustine
Niraparib
Niraparib/abiraterone acetate
Nitrogen mustard
Nitrosourea
Nucleoside
Nystagmus
Obecabtagene autoleucel
Obinutuzumab
Oblimersen
Ocrelizumab
Ocrelizumab/hyaluronidase
Odulimomab
Ofatumumab
Olaparib
Oligoclonal band
Olokizumab
Olutasidenib
Omacetaxine mepesuccinate
Omalizumab
Opinercept
Oprozomib
Optic neuritis
Orphan disease
Orphan drug
Ortataxel
Otelixizumab
Oxaliplatin
Ozanimod
P53
PARP inhibitor
PDE4 inhibitor
PMC (identifier)
PMID (identifier)
Paclitaxel
Padeliporfin
Pain
Palbociclib
Panobinostat
Parenteral
Pascolizumab
Pathophysiology of multiple sclerosis
Peficitinib
Pegaspargase
Pegcetacoplan
Pelizaeus–Merzbacher disease
Pemetrexed
Pentostatin
Pexelizumab
Pharmacokinetics
Phases of clinical research
Phosphodiesterase inhibitor
Phosphoinositide 3-kinase inhibitor
Photodynamic therapy
Photosensitizer
Pimecrolimus
Pipobroman
Pirarubicin
Pirfenidone
Pixantrone
Plasma protein binding
Platelets
Platinum-based antineoplastic
Plicamycin
Plitidepsin
Podophyllum peltatum
Polyclonal antibodies
Pomalidomide
Ponesimod
Porfimer sodium
Porphyrin
Poser criteria
Pralatrexate
Prednimustine
Pregnancy category
Prescription drug
Procarbazine
Progressive multifocal leukoencephalopathy
Proteasome inhibitor
Protein kinase inhibitor
PubChem
Purine analogue
Purine synthesis inhibitor
Pyrimidine analogue
Rabacfosadine
Radiologically isolated syndrome
Raltitrexed
Ranimustine
Ravulizumab
Receptor antagonist
Red blood cells
Regulation of therapeutic goods
Relapsing-remitting multiple sclerosis
Research in multiple sclerosis
Reslizumab
Retinoid
Retinoid X receptor
Ribociclib
Ribonucleotide reductase inhibitor
Ridaforolimus
Rilonacept
Risankizumab
Ritlecitinib